Yttrium (90Y) tacatuzumab tetraxetan

Yttrium (90Y) Tacatuzumab Tetraxetan: An Advanced Cancer Therapeutic Agent

Yttrium (90Y) tacatuzumab tetraxetan, commercially known as AFP-Cide, represents a pioneering advancement in the realm of cancer therapeutics. It is a monoclonal antibody that has been humanized and subsequently conjugated to a chelator to enable the binding of a potent radioisotope, aimed at targeting and eradicating tumor cells.

Mechanism of Action

The primary component of this drug, tacatuzumab, is a humanized monoclonal antibody. Monoclonal antibodies are proteins designed to recognize and bind to specific targets on the surface of cancer cells<ref>Reichert, J. M. (2016). Antibodies to watch in 2016. MAbs, 8(2), 197-204.</ref>.

For enhanced therapeutic efficacy, tacatuzumab is conjugated with tetraxetan, a chelating agent. This chelator facilitates the binding of the yttrium-90 radioisotope to the antibody<ref>Scheinberg, D. A., & Villa, C. H. (2019). Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews Clinical Oncology, 16(5), 312-325.</ref>. Yttrium-90, being a beta-emitting isotope, releases radiation that can destroy tumor cells, thus offering targeted radiation therapy<ref>Wright, C. L., & Werner, T. J. (2019). Therapeutic applications of yttrium-90 radioembolization. Future Oncology, 15(6), 637-652.</ref>.

Applications in Oncology

The conjugation of the tacatuzumab antibody with yttrium-90 leverages the specificity of the antibody to direct the cytotoxic effects of radiation to the tumor, sparing most of the surrounding healthy tissues. This targeted approach potentially offers:

• Reduced side effects compared to non-targeted radiation therapies.
• Enhanced tumor cell eradication due to the direct delivery of the radioactive agent.

While Yttrium (90Y) tacatuzumab tetraxetan is primarily intended for cancer treatment, the specific types of cancers it best addresses and the stages at which it is most effective would need further clinical validation.

Current Status and Development

As with many experimental therapeutics, Yttrium (90Y) tacatuzumab tetraxetan is undergoing rigorous evaluation in both preclinical studies and clinical trials to ascertain its safety, efficacy, and optimal administration regimen.

It's crucial to note that while the promise of such therapies is high, their transition from the laboratory to clinical practice requires extensive research and iterative refinement to ensure both safety and therapeutic efficacy<ref>Kontermann, R. E. (2017). Strategies for extended serum half-life of protein therapeutics. Current opinion in biotechnology, 48, 152-159.</ref>.

Conclusion

The development of Yttrium (90Y) tacatuzumab tetraxetan epitomizes the advancements in precision oncology, where targeted therapies are poised to revolutionize cancer treatment. As research progresses, this drug may offer a beacon of hope for patients battling certain types of cancers.

References

<references />

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Structure of Y-90 tacatuzumab tetraxetan